EDIT vs UPST · rev $32.3M vs P/E 74, rev $636.5M
Editas Medicine Inc (EDIT) versus Upstart Holdings Inc (UPST) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Upstart Holdings Inc (UPST) is a credit services company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported UPST revenue for 2024-12-31 was $636.5M. Net income was -$128.6M. Revenue was up 23.9% from 2023-12-31 to 2024-12-31. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
EDIT currently screens at market cap $375.2M. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
Not investment advice. Open the EDIT and UPST stock pages for the full models.
Not investment advice.